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Abstract
Objective To assess the ocular effects and safety profile of chronic
sildenafil oral dosing in patients with pulmonary arterial hypertension.
Design 12 week, double masked, randomised, placebo controlled, phase
III trial with open label extension.
Setting 53 institutions worldwide.
Participants 277 adults with idiopathic pulmonary arterial hypertension
or pulmonary arterial hypertension associated with connective tissue
disease or after congenital heart disease repair (mean pulmonary artery
pressure ≥25 mm Hg; pulmonary capillary wedge pressure ≤15 mm Hg
at rest).
Interventions During the double masked study, oral sildenafil 20 mg,
40 mg, or 80 mg or placebo (1:1:1:1) three times daily for 12 weeks was
added to baseline drug treatment. In the extension study, the placebo,
20 mg and 40 mg groups received 40 mg three times daily titrated to 80
mg three times daily at week 6. After unmasking, the dose was titrated
according to clinical need.
Main outcome measure Ocular safety (ocular examinations, visual
function tests, participants’ reports of adverse events, and visual
disturbance questionnaire completed by investigators) by treatment
group at 12 weeks, 24 weeks, 18 months, and yearly.
Results Findings of the objective assessments—that is, intraocular
pressure and visual function tests (visual acuity, colour vision, and visual
field)—were similar across groups (20 mg, n=69; 40 mg, n=67; 80 mg,
n=71; placebo, n=70). No clinically significant changes occurred between
baseline and 12 weeks, except for an efficacy signal in contrast sensitivity
for the sildenafil 40 mg three times daily group. In right eyes, changes
in intraocular pressure from baseline to week 12 ranged from a mean
of −0.5 (95% confidence interval −1.3 to 0.2) mm Hg with placebo, −0.2
(−0.9 to 0.5) mm Hg with sildenafil 40 mg, and −0.1 (−0.7 to 0.5) mm
Hg with 80 mg to 0.3 (−0.4 to 0.9) mm Hg with sildenafil 20 mg (the
approved dose for pulmonary arterial hypertension). Mean changes from
baseline to week 12 in contrast sensitivity in right eyes were −0.02 (SD
0.12) in the sildenafil 20 mg three times daily group compared with −0.05
(0.18) in the placebo group (P=0.044). Percentages of participants with
deterioration in visual acuity (Snellen) from baseline to week 12 ranged
from 10% (n=7) in the placebo group to 3% (n=2) in the sildenafil 20 mg
three times daily group; the same percentages had visual field changes
from normal to abnormal during the period in these two groups. The
investigators did not deem any findings on colour vision assessment to
be clinically significant. Findings of the objective assessments in the 40
mg and 80 mg three times daily sildenafil treatment groups and in left
eyes were not substantially different, nor were any measures different
throughout the open label extension compared with week 12. However,
objective data were limited after month 18, as most participants had
missing data or visual parameters were no longer collected by
investigators. Incidence of ocular adverse events reported on the case
report forms and assessed by the investigator was low with all doses,
but a modest, dose related incidence of chromatopsia, cyanopsia,
photophobia, and visual disturbance was reported with 80 mg three
times daily consistent with the indicated dosing for erectile dysfunction.
Retinal haemorrhages, captured on funduscopy, occurred in 2% (4/207)
of sildenafil treated participants and none in the placebo group during
the double masked study and in 4% (10/259) during the open label
extension.
Conclusions Sildenafil dosing up to 80 mg three times daily is safe and
well tolerated from an ocular perspective in patients with pulmonary
arterial hypertension. Daily chronic dosing in this patient population was
not associated with visual change and had no detrimental effect on best
corrected visual acuity, contrast sensitivity, colour vision, or visual field,
or on slit lamp examinations, funduscopy, or intraocular pressure during
the duration of this study.
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Research
RESEARCHTrial registration Clinical trials NCT00644605 and NCT00159887.
Introduction
Orallyadministeredselectivephosphodiesterasetype5inhibitors
developedforthemanagementoferectiledysfunctionhavebeen
used more recently as a treatment for pulmonary arterial
hypertension.Sildenafilcitrate(Revatio,PfizerInc,NewYork)
isapprovedinseveralcountriesworldwide,includingtheUnited
StatesandEurope,forthisindication.Thisclassofvasodilators
is capable of crossing the blood-retina barrier.
1
Phosphodiesterasesproducevasoconstrictionofsmoothmuscle
cells through their ability to degrade cyclic nucleotides such as
cyclicguanosinemonophosphate.Asnitricoxideactstoincrease
concentrations of cyclic guanosine monophosphate through
stimulation of guanylate cyclise,
2 3 and phosphodiesterase type
5 hydrolyses cyclic guanosine monophosphate, the combined
effect of these changes is a significant lowering of cyclic
guanosinemonophosphateconcentrations.
1 4Downstreameffects
of this reduction in cyclic guanosine monophosphate through
phosphodiesterase type 5 activation include increases in
intracellularcalciumandpotassiumleadingtovasoconstriction
and the promotion of vascular smooth muscle cell proliferation
and vascular fibrosis.
5-7 By increasing cyclic guanosine
monophosphate concentrations, phosphodiesterase type 5
inhibitors promote systemic arterial smooth muscle relaxation
and vasodilatation while simultaneously preventing cellular
proliferation; they thus offer the possibility of alleviating
pulmonary arterial hypertension.
6
Pulmonary arterial hypertension is characterised by restricted
flow through the pulmonary circulation with resultant increase
in pulmonary vascular resistance and, ultimately, right heart
failure.
8 Although the underlying pathophysiology is not
completely understood, the key features are the decreased
expressionofnitricoxidesynthasebyendothelialcellstogether
withincreasedexpressionofphosphodiesterasetype5insmooth
muscle cells of the pulmonary artery and right ventricular
myocardium.
5 6 9-12
Owing to the widespread use of single dose sildenafil as a
treatment for erectile dysfunction, clinical studies and case
reports have focused on the possible systemic and ocular side
effects (including those on visual function) associated with
sildenafil and other phosphodiesterase type 5 inhibitors (for
recent reviews, see Laties 2009
1 and Kerr and Danesh-Meyer
2009
4).Phosphodiesterasetype5isexpressedontheretinaland
choroidal vasculature (smooth muscle and endothelial cells) as
wellasonganglionandbipolarcells.Concernshavebeenraised
about potential ocular side effects of sildenafil that derive
directly from its effect on ocular vasculature and from its
concurrent crossover inhibition of phosphodiesterase type 6,
which is expressed in the retinal photoreceptor layer (both rods
and cones),
13 with a potency approximately 10-fold less than
that for phosphodiesterase type 5.
13 14 The most common visual
disturbancereportedisadosedependentreversibleimpairment
of colour discrimination, principally in the blue-green to
blue-purple range.
1 15 16 Transient electroretinographic changes
have been reported with sildenafil, including increases in light
sensitivity,
17 18possiblyreflectinginhibitionofphosphodiesterase
type 6,
4 but no other effects on psychophysical measures of
visual function have been found.
4 19 A recent study in sheep
showed increased intraocular pressure within one hour of a
dose
20;however,inhumans,clinicallyimportantadverseeffects
of sildenafil on intraocular pressure have not been reported.
21-23
Studies of the effects of sildenafil on ocular vasculature have
nothadconsistentresults.Severalreportsshowlittleornoeffect
on various measures related to vessel diameter and ocular
circulation.
24-27 By contrast, other studies have measured
increases in one or both of these vascular properties after oral
intermittentsildenafiltreatment.
13 28-33Theinconsistenciesamong
these study results may reflect variations in experimental
approaches, instrumentation, and length of dosing as well as
the short lived and relatively modest amplitude of the changes
measured.
19Rarevasculareventsthathavebeenreportedincase
studies include non-arteritic anterior ischaemic optic
neuropathy,
1 central serous chorioretinopathy,
34 branch retinal
artery occlusions,
35 36 and third nerve palsy.
37 38
To evaluate potential effects on visual function and the ocular
safety profile of sildenafil during chronic oral use, the pivotal
placebo controlled trial of sildenafil for the treatment of
pulmonary arterial hypertension and its open label extension
included ophthalmic examinations and assessments of visual
function. During the double masked study, sildenafil doses of
20,40,or80mgorplacebowereadministeredorallythreetimes
dailyfor12weeks.
39Intheextension,doseswerefirstup-titrated
toamaximumof80mgthreetimesdailyatweek6inamasked
fashion while the 80 mg group had sham titration. After the last
participantinthedoublemaskedstudyhadcompleted12weeks
of treatment, doses in the extension study were unmasked and
thencouldbeadjustedaccordingtoclinicalneedtoamaximum
of 80 mg three times daily or a minimum of 20 mg three times
daily. We report here the ocular findings.
Methods
The initial 12 week, double masked, placebo controlled study
of sildenafil citrate for pulmonary arterial hypertension was
conducted in 53 centres in Australia, Belgium, Brazil, Canada,
the Czech Republic, Denmark, France, Germany, Hong Kong,
Hungary, Ireland, Israel, Italy, Mexico, the Netherlands,
Norway,thePhilippines,Poland,Singapore,SouthAfrica,South
Korea, Spain, Sweden, the United Kingdom, and the United
States between October 2002 and November 2003
(NCT00644605).Participantswhocompletedthedoublemasked
study could enrol in an open label, optimised dose extension
study (NCT00159887). All participants gave written informed
consent. Sildenafil has been widely prescribed since it was
introducedintothemarketin2005,andrecentdataindicatethat
sildenafil20mgthreetimesdailyhasmorethan118000patient
years of experience globally
The methods and primary results of both the double masked
study and the extension have been reported.
39 A summary of
the methods and details of the ophthalmologic assessments
follows.
Adultparticipantswithpulmonaryarterialhypertension,defined
as a mean pulmonary artery pressure of at least 25 mm Hg and
a pulmonary capillary wedge pressure of 15 mm Hg or lower
at rest, were eligible. Participants could have idiopathic
pulmonaryarterialhypertension,pulmonaryarterialhypertension
associatedwithconnectivetissuedisease,orpulmonaryarterial
hypertension following surgical repair of congenital systemic
topulmonaryshuntsatleastfiveyearspreviously.Patientswith
a six minute walking distance of less than 100 m or more than
450mwereexcluded;intravenousepoprostenol,oralbosentan,
intravenous or inhaled iloprost, or subcutaneous treprostinil, as
well as supplementation with L-arginine, were prohibited.
Warfarin, calcium channel blockers, digoxin, oxygen, and
diuretics were allowed during the study. Entry criteria were
unrelated to history of ocular pathology, macular degeneration,
glaucoma, or ocular hypertension or to baseline intraocular
pressure.
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RESEARCHAt baseline, participants were randomised (1:1:1:1) to 20, 40,
or80mgofsildenafilorplaceboadministeredthreetimesdaily.
Participants randomised to receive 80 mg initially received 40
mg for one week and then were titrated to 80 mg. All other
participants had a sham titration. Study drug was added to the
participant’sbaselinedrugtreatmentregimenandadministered
for 12 weeks.
The study used an automated interactive voice response system
incorporating a central randomisation and drug supply scheme.
The randomisation scheme was stratified by baseline walking
distance (<325 m, ≥325 m) and cause (primary pulmonary
arterial hypertension, pulmonary hypertension secondary to
connectivetissuedisease,pulmonaryhypertensionwithsurgical
repair).Theinteractivevoiceresponsesystemassignednumbers
sequentially to the participants from the appropriate
randomisation stratification group as they were determined to
be eligible for treatment by the investigator. The drug supply
scheme consisted of a list of pack numbers and corresponding
treatment types. A unique pack number identified each drug
pack. The interactive voice response system assigned
participants a pack number from the list corresponding to the
treatment assigned. At the start of the masked study, the study
site was instructed on the method for unmasking, which was
either a manual or an electronic process. Masking codes were
brokenonlyinemergencysituationsforreasonsofparticipants’
safety. The investigator was encouraged to contact the study
sponsor before unmasking. When the code was broken, the
reason was fully documented and entered on the study report
form.
In the open label extension, the first pivotal portion involved a
forced masked upward titration (figure⇓). The participants
originally randomised to receive placebo or sildenafil 20 or 40
mg in the double masked study received a starting dose of
sildenafil 40 mg three times daily during the first six weeks,
after which the dose was increased to 80 mg three times daily.
Those randomised to 80 mg sildenafil three times daily in the
double masked study remained on this dose for the first six
weeks of the extension and had a sham dose escalation. One
down-titration was permitted for tolerability during the first 12
weeks of the extension study. The open label extension study
was unmasked after the last participant had completed at least
threemonthsofextensiontreatment.Afterunmasking,sildenafil
was titrated according to clinical need as determined by the
investigator and the participant to a maximum of 80 mg three
times daily or to a minimum of 20 mg three times daily.
Participants were to continue taking their optimised dose of
sildenafil until the last enrolled patient had completed three
yearsoftreatmentoruntilsildenafilwasshowntobeineffective,
poorlytolerated,orunsafeinthetreatmentofpulmonaryarterial
hypertension.
All doses were to be administered at least six hours apart.
Participantswereaskedtorecorddosestakenintheirdiarycards
and took the first dose in the morning at the hospital at baseline
and weeks 8 and 12. Participants were asked to return unused
drugateachvisitandweregivensufficientsupplyfortreatment
until the next visit.
During the initial double masked portion of the study,
ophthalmologists did ophthalmic examinations and visual
function tests in both eyes at baseline and week 12. The
ophthalmic examinations included external inspection of the
eye,slitlampbiomicroscopyoftheanteriorportion,funduscopy
to examine the posterior segment, and measurement of
intraocularpressurebyGoldmannapplanationtonometry.Visual
function was evaluated with best corrected visual acuity testing
usingaSnelleneyechart,theFarnsworth-MunsellD15huetest
for colour, the Pelli-Robson test of contrast sensitivity, and the
Humphrey visual field test. The timing of ocular examinations
and assessments in relation to administration of oral sildenafil,
diurnal intraocular pressure variability, or both was not
pre-specified. Intraocular pressure changes of less than 4 mm
Hgfrombaselinetoweek12werepredefinedasbeingclinically
not significant. Investigators recorded all observed and
volunteered adverse events, the severity (mild, moderate, or
severe) of the events, and their opinion of the relation of the
events to study treatment on case report forms. We coded
adverse events centrally using the Medical Dictionary for
Regulatory Activities. In addition, the investigator completed
a four item visual disturbances safety questionnaire if a
participant reported an ocular adverse event. The questionnaire
included items reflecting the timing, duration, and impact of
the event; most responses were recorded in check boxes, but
the instrument also included an open ended question on the
effect of the symptom on the participant’s day to day life. In
the open label portion of the extension study, once all
participantshadcompletedtheirfirst12weeks,thesameocular
examinations including slit lamp, funduscopy, intraocular
pressure, and visual function measurements were done in both
eyes at week 12 (corresponding to week 24 of the overall trial),
month 15 (corresponding to month 18 of the overall trial), and
yearly thereafter. At the baseline visit, testing was done before
the initial dose of sildenafil was administered, whereas
evaluations at subsequent visits were done after the dose.
We summarised the results of the visual function assessments
and the visual disturbance questionnaire by randomised
treatmentgroup.Wedidnotanalysebetweengroupdifferences
with statistical hypothesis testing owing to low power. Ocular
adverse event data collected by the investigator and reported
onthecasereportformaresummarisedpernumber(percentage)
of participants and not per eye. For intraocular pressure and
visual function assessments (such as visual acuity and contrast
sensitivity), we report data for the right eye unless results for
the left eye seemed to be clinically significantly different.
Results
In all, 278 participants were randomly assigned to receive
sildenafil in doses of 20 mg (n=69), 40 mg (n=68), or 80 mg
(n=71) or to receive placebo (n=70), and 277 participants took
at least one dose of study drug. A total of 265 participants
completed the 12 week randomised study, and 259 entered the
extension.Themedianlengthoftreatmentduringtheextension
was 1171 (range 1-1442) days, and 222 participants completed
one year of treatment with sildenafil monotherapy.
39 However,
data reflecting the results of the visual function assessments
after month 18 were limited given that most participants had
data missing or the visual parameters were no longer collected
by investigators. Subjective adverse event data (that is, reports
by participants) were collected throughout the double masked
and open label studies.
Baseline characteristics were similar across treatment groups
(table 1⇓). About three quarters of participants were female,
andtheoverallmeanagewasapproximately49years.Between
60% and 65% of participants in each group were diagnosed as
having idiopathic pulmonary arterial hypertension, and 58%
overallwereclassifiedasWorldHealthOrganizationfunctional
class III. Only six participants had pre-existing glaucoma or
ocularhypertension.Acrosstreatmentgroups,themeanbaseline
intraocular pressure was approximately 15 mm Hg, and 71%
of participants had normal visual fields at baseline as assessed
by clinical investigators.
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RESEARCHAtbaselineophthalmicexaminations,themostprevalentocular
findingreportedwasdilatedepiscleralvessels(righteye:44/260,
17%; table 2⇓). Conjunctival injection and abnormal blood
vessels were also relatively common, with incidences of 13%
(34/260) and 12% (32/260). Retinal vein engorgement and
conjunctival oedema were relatively rare at baseline. The
baseline incidence of dilated episcleral blood vessels,
conjunctival injection, and abnormal blood vessels was
somewhathigherinparticipantswithprimarypulmonaryarterial
hypertensionthaninthosewithpulmonaryarterialhypertension
associated with connective tissue disease (table 2⇓). For
example, conjunctival injection was present in the right eye of
22/164 (13%) participants with primary pulmonary arterial
hypertension and in 7/81 (9%) with pulmonary arterial
hypertension associated with connective tissue disease. The
baseline incidence of retinal vein engorgement was lower in
participantstakingwarfarin(righteye:2/114,2%)thaninthose
nottakingwarfarin(righteye:8/146,6%),whereastheincidence
of dilated episcleral vessels was higher in participants taking
warfarin (right eye: 21/114, 18%) than in those not taking
warfarin (right eye: 23/146, 16%).
12 week, randomised, double masked pivotal
study
Inalltreatmentgroups,findingsoftheophthalmicexaminations
(external inspection, slit lamp, funduscopy, and intraocular
pressure) and visual function tests were little changed from
baseline to week 12 in the double masked study. No clinically
significantchangesfrombaselinetoweek12inmeanintraocular
pressure occurred in either eye in any treatment group. In right
eyes, the modest changes in intraocular pressure that did occur
ranged from a mean change of −0.5 (95% confidence interval
−1.3 to 0.2) mm Hg with placebo, −0.2 (−0.9 to 0.5) mm Hg
with sildenafil 40 mg, and −0.1 (−0.7 to 0.5) mm Hg with 80
mg,toameanchangeof0.3(−0.4to0.9)mmHgwithsildenafil
20 mg. Most participants in all groups had “clinically
non-significant” changes in intraocular pressure (<4 mm Hg)
from baseline to week 12.
We found no change in log contrast sensitivity (<0.15) at week
12 relative to baseline in most participants in any treatment
group (table 3⇓). The percentages of participants showing
deterioration in log contrast sensitivity from baseline to week
12 were similar in the 80 mg sildenafil and placebo groups and
were somewhat lower in the other sildenafil dose groups. In the
righteye,themeanchangefrombaselinetoweek12was−0.02
(SD 0.12), 0.02 (0.14), and −0.02 (0.14) in the sildenafil 20,
40, and 80 mg groups, compared with −0.05 (0.18) in the
placebogroup(P=0.044,P<0.001,andP=0.093versusplacebo).
In right eyes, proportions of responders (positive change in log
contrast sensitivity ≥0.15) in the sildenafil treatment groups
compared with placebo were 5% versus 3% (P=0.638) for 20
mgthreetimesdaily,12%versus3%(P=0.044)for40mgthree
times daily, and 8% versus 3% (P=0.222) for 80 mg three times
daily. In left eyes, the corresponding proportions of responders
in the sildenafil treatment groups compared with placebo were
5% versus 2% (P=0.305), 11% versus 2% (P=0.026), and 5%
versus 2% (P=0.290).
Treatment with sildenafil for 12 weeks did not seem to alter
visual acuity at any dose tested. Most participants in all
treatment groups showed no change or indeterminable change
in the number of lines read on the Snellen chart from baseline
to week 12 (table 3⇓). The percentage of participants who
showed an algebraic negative change from baseline in visual
correction or deterioration in either eye, defined as a decrease
of one or more lines read in those with a baseline assessment
between 6/6 and 6/60, was also similar across groups. Most
participants with normal visual fields at baseline continued to
have normal visual fields at week 12 (table 4⇓). We found no
apparent differences among treatment groups in the overall
frequency of visual field changes.
We plotted results of colour vision assessments manually for
each participant. One of the authors (AML) assessed all
abnormalfindingsandchangesfrombaseline.Wemadequeries
to investigators for all identified adverse events, and they said
thatnoclinicallysignificantfindingsoccurred.Wethenarchived
the plots.
The incidence of reported and observed ocular adverse events
was low (table 5⇓). Ocular adverse events that did occur were
of mild to moderate severity in all cases, with the exception of
one participant in the sildenafil 80 mg group who developed
severe photophobia 72 days after the start of the study. We saw
a modest, dose related increase in the incidence of
phosphodiesterase type 6 mediated effects consistent with the
known ocular profile of single dose sildenafil for erectile
dysfunction, including chromatopsia, cyanopsia, photophobia,
visual brightness, and visual disturbance; the incidence of each
of these effects was 7% or lower with sildenafil 80 mg and less
than 5% with sildenafil 40 mg. For the sildenafil 20 mg three
times daily group, which received the clinically approved dose,
as well as for those receiving placebo, these incidences were
less than 2%. Four cases of retinal haemorrhage were observed
in participants receiving warfarin, one each in the sildenafil 20
mg and 80 mg groups (incidence=1%) and two in the sildenafil
40 mg group (incidence=3.0%).
Overall, the frequency of characteristic ocular anatomical
findings seen in right heart failure/pulmonary arterial
hypertension at baseline and at week 12 seemed not to differ
among treatment groups for right eyes (table 6⇓). No cases of
serous retinal or choroidal detachment were observed in either
eyeinanytreatmentgroupatbaseline,butbothconditionswere
detected at week 12 in the left eye of one participant with
pulmonary arterial hypertension associated with connective
tissue disease in the sildenafil 40 mg group (incidence for
each=2%). The upward drift in conjunctival injection was
somewhat greater in participants treated with sildenafil relative
to those treated with placebo; however, we found no evidence
of a significant dose-response relation. We noted a modest
increase in the incidence of conjunctival oedema in sildenafil
treatedparticipantsbetweenbaselineandweek12,butwefound
no evidence of a dose-response relation. A slight increase in
dilatedepiscleralvesselsoccurredinbothsildenafilandplacebo
treated groups between baseline and week 12; the magnitude
of the increase seemed similar in the active treatment and
placebo groups, and the increase was not dose dependent in the
sildenafil groups. The incidence of abnormal blood vessels
remainedfairlyconstantfrombaselinetoweek12intheplacebo
group as well as in all the sildenafil dose groups. The incidence
of retinal vein engorgement was relatively low in all groups
both at baseline and at week 12. For each of these measures,
wesawasimilarpatterninparticipantswithprimarypulmonary
arterial hypertension and in those with pulmonary arterial
hypertension associated with connective tissue disease.
Open label, optimised dose extension
Doses of 12 (5%) participants were titrated downward from
sildenafil 80 mg three times daily during the first 12 weeks of
open label treatment. Table 7⇓ shows a cross tabulation of the
doublemaskedstudydosegroupsbydoseduringtheopenlabel
study. As in the double masked pivotal study, sildenafil
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RESEARCHmaintained a favourable ocular safety profile throughout the
open label phase of the optimised dose extension. In both eyes,
we found no clinically significant changes in the results of the
ophthalmic examinations and or visual function tests. At week
24, three quarters (163/218) of participants showed no change
in intraocular pressure, defined as a change of less than 4 mm
Hg relative to baseline. Among those who did show a change
of 4 mm Hg or more, intraocular pressure was more likely to
decrease than to increase. Likewise, findings with regard to
contrast sensitivity, visual acuity, colour vision, and visual field
measurements were not substantially different at week 24
compared with week 12.
The incidence of reported and observed ocular adverse events
waslow.Asexpected,amodestincidenceofphosphodiesterase
type 6 mediated effects was noted at the last visit (table 8⇓).
Theincidenceofretinalhaemorrhageremainedlowduringopen
label treatment, with a total of 11 (4%) cases, which included
three participants who were receiving warfarin. Fifty per cent
of the noted ocular haemorrhages, including retinal
haemorrhages, that occurred as adverse events in participants
taking warfarin were noted to have resolved at the time of each
participant’s last visit.
After 24 weeks and 18 months of total follow-up, the incidence
ofcharacteristicocularanatomicalfindingsseeninparticipants
with right heart failure pulmonary arterial hypertension was
generally similar to that noted after 12 weeks of double masked
treatment. At week 24, serous retinal detachment and choroidal
detachment were observed in both eyes of the participant who
had shown these abnormalities in the left eye only at week 12;
choroidal detachment was observed in the right eye of one
additionalparticipant.Thus,atweek24,theincidenceofserous
retinaldetachmentwas0.4%(1/239)forbothleftandrighteyes,
and the incidence of choroidal detachment was 0.4% (1/239)
for left eyes and 0.8% (2/239) for right eyes. Both conditions
subsequently resolved in these two participants, and no cases
of either serous retinal detachment or choroidal detachment
were reported at month 18 (incidence: either eye=0%). The
incidence of conjunctival injection was consistent across the
open label extension treatment (about 17%), and that of
conjunctival oedema was low at week 12 and decreased
moderately at week 24 and month 18 (right eye: 2% (4/256),
1% (3/239), and 1% (1/117), respectively). The incidence of
dilated episcleral blood vessels was higher at week 12 than at
week 24 or month 18 (right eye: 22% (56/256), 18% (44/239),
and 15% (17/117), respectively). The incidence of abnormal
blood vessels decreased slightly from week 12 to week 24 but
was similar to the baseline level at month 18 (right eye: 12%
(31/256),8%(20/239),and13%(15/117),respectively),whereas
the incidence of retinal vein engorgement was lowest at month
18 (right eye: 6% (15/256), 6% (15/239), and 3% (4/117)).
Discussion
The principal finding of both the pivotal trial and its open label
extension is that chronic oral sildenafil treatment did not lead
to any significant ocular safety signals on ocular examination,
on assessment of visual function, or through visual disturbance
questionnaires. With respect to changes in subjective visual
function,theonlyeffectwasalow,dosedependent,andinmany
cases reversible incidence of the transient phosphodiesterase
type 6 mediated effects that have been reported from clinical
experience with single use sildenafil in the treatment of erectile
dysfunction.
14 Moreover, in the pivotal trial, treatment with the
clinically approved dose, 20 mg three times daily, resulted in a
frequency of these effects that was indistinguishable from that
withplacebotreatment.Similarly,wefoundnoevidentadverse
effect of chronic sildenafil on visual acuity or contrast
sensitivity.Notably,sildenafil40mgthreetimesdailyimproved
log contrast sensitivity compared with placebo over 12 weeks.
Although it is a functional test associated with variability and
noise, contrast sensitivity provides an objective measure of
retinal/neuronal/photoreceptor function that can be affected by
microvascular changes.
40 41
Inadditiontohavingnosignificanteffectonmeasuresofvisual
function, chronic sildenafil treatment in this study was not
associatedwithanincreasedincidenceofreportedandobserved
ocularadverseevents,andtheincidencesofretinalhaemorrhage,
conjunctival oedema, and serous retinal and choroidal
detachment were low, with no evident effect on intraocular
pressure in objective ophthalmic examinations. However, the
trialwasnotadequatelypoweredtodetectsignificantdifferences
between groups for ocular events occurring at low frequency,
andatruecausalitycannotbedetermined.Retinalhaemorrhage
is an ocular finding that has been described in patients with
pulmonary arterial hypertension and in those with connective
tissue disease.
42-45 Risk factors for retinal haemorrhage are
numerous and include sudden changes in ocular or vascular
pressures, such as those that occur during vomiting, trauma, or
violentexercise.Theyalsoareseenatbothextremesofvascular
perfusion pressure, either arterial or venous, being noted both
in acute systemic hypertension and in chronic venous
insufficiency. Anticoagulants, which are commonly used by
patients with pulmonary arterial hypertension, are associated
with an increased risk of ocular and retinal haemorrhages. In
virtually all cases, responsibility lies with the risk imposed by
the prolonged coagulation time brought about by warfarin
treatment. Moreover, in large general population surveys,
microvascular abnormalities, including small retinal
haemorrhages, are consistently noted in 2-4% of people
surveyed.
46 Commonly, retinal haemorrhages can be incidental
clinical findings that resolve without sequelae.
In this study, we also saw the low incidence of serous retinal
and choroidal detachments that is implied from case reports of
untreated pulmonary arterial hypertension.
42 43 47-49 Those that
occurred were most likely due to the underlying systemic
pathology,possiblyresultingfromalterationsinchoroidalblood
flow, such as increased choroidal pressure, venous stasis, and
uveal effusions.
50 Dilated episcleral veins and conjunctival
injection were the most common observed ocular anatomical
findings in both untreated and treated participants with
pulmonary arterial hypertension in this study. With respect to
the incidence of dilated episcleral vessels and retinal
engorgement, these were similar in both sildenafil and placebo
groups during the double masked study and actually declined
during the open label extension. Whether these decreases were
treatmentassociatedeffectsduetochangesintheocularvascular
stasis, vascular changes associated with the severity and
chronicityoftheunderlyingpulmonaryarterialhypertension,
49 50
or the result of attrition of participants is, however, unclear. The
upward drift in the incidence of conjunctival injection in both
treatment groups at 12 weeks seemed to be slightly greater in
participantsreceivingsildenafil.However,acrossthe15months
of the open label extension, the incidence was consistent across
treatment groups. As conjunctival oedema is a less specific
ocular manifestation of pulmonary arterial hypertension, this
finding is difficult to assess.
Relation to other studies
Asdiscussedabove,thefindingsofthisstudyareinaccordwith
existingreportsintheliteratureoftheshorttermeffectsofsingle
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RESEARCHuse sildenafil on measures such as colour discrimination and
visual sensitivity.
4 19 Moreover, a recent study examining long
term use of sildenafil in healthy people found no significant
difference from placebo in such measures of visual function as
visual acuity, static perimetry, or colour discrimination or in
key electroretinographic variables,
23 whereas a study of five
patientswithpulmonaryarterialhypertensiontakinghighdoses,
up to 225 mg/day for one to four years, also found only modest
electroretinographic changes in cone function and no evidence
of serious visual toxicity.
51
One visual disorder, non-arteritic anterior ischaemic optic
neuropathy, has been reported as a rare event (18 instances in
all)aftersingleusesildenafil.
1Althoughnodefinitivelinkexists
between these occurrences and the drug, the product label
includes advice to discontinue use of sildenafil in the event of
sudden loss of vision.
1 14 Optic nerve heads that are relatively
small with small cup to disc ratios have been reported to be at
risk of non-arteritic anterior ischaemic optic neuropathy.
52
Estimates of the overall incidence of non-arteritic anterior
ischaemicopticneuropathyintheUnitedStatesrangefrom2.52
to 11.8 men and from 2.14 to 9.2 women per 100 000 of the
population aged over 50
53 54; the comparable estimate in China
for adults aged over 40 is six per 100 000.
55 With intermittent
usage of sildenafil, however, the estimated incidence of
non-arteriticanteriorischaemicopticneuropathyisonly2.8per
100 000 patient years of use.
1 56 Moreover, many of the risk
factors for non-arteritic anterior ischaemic optic neuropathy,
such as diabetes, hypertension, hypercholesterolaemia,
atherosclerosis,ischaemicheartdisease,stroke,pro-thrombotic
factors, raised homocysteine concentrations, sleep apnoea, and
nocturnal hypotension, are also risk factors for erectile
dysfunction,
1 so that assessing whether occurrences of
non-arteritic anterior ischaemic optic neuropathy should be
attributed to the drug or to the underlying systemic vascular
pathology is difficult. Although the potential for inducing
non-arteritic anterior ischaemic optic neuropathy in patients
with pulmonary arterial hypertension cannot be discounted,
57
on the basis of this study of chronic sildenafil use, it seems
likely that in patients with similar characteristics, no increased
risk of non-arteritic anterior ischaemic optic neuropathy exists
for at least 18 months.
Strengths and limitations
A decision was made during the design of this double blind
study and open label extension not to do electroretinographic
testing for several reasons. Firstly, in preclinical studies with
two species, no evidence existed of general ocular toxicity or
of specific retinal structural changes with long term, high dose
sildenafiladministration.
58Furthermore,theresultsfromaseries
of electroretinographic studies in humans receiving sildenafil
are similarly reassuring, showing either no effect at all or
modest, fully reversible, transient electroretinographic changes
that do not translate into significant effects on visual
performance.
59-61 Finally, the risk of retinal toxicity seems to be
exceedingly small, whereas the constraints on and limitations
of clinical electroretinographic testing at multiple sites are
considerable. Transportation of these seriously ill patients to
certified centres for electroretinographic testing would be
necessary, and the underlying systemic disease and ocular
manifestations could contribute to technical difficulties with
administration and interpretation of the test.
Severallimitationstothestudyshouldbenoted.Firstly,because
ocular safety, including visual function, was not the primary
objectiveofthisphaseIIIstudy,thesamplesizecalculationwas
notbasedonocularendpoints.Webelievethatthelargeamount
ofdataavailableisgenerallysufficientforassessmentofocular
safety with sildenafil use in patients with pulmonary arterial
hypertension, although the power to detect rare, serious events
was lacking. Other limitations were associated with the timing
of the ocular assessments, the number of examinations/tests
done, and the omission of diagnostic procedures such as
electroretinographicandstandardiseddigitalfundusphotosthat
would have provided additional information about vascular or
optic nerve effects. For example, the fact that only one
intraocular pressure measurement was taken was reasonable,
but the timing of this measurement in relation to diurnal
intraocular pressure variability should have been pre-specified.
Also,severalmeasurementsofintraocularpressureshouldhave
been taken at each sitting (right eye, followed by left) and the
mean presented. In addition, the Humphrey visual field
examination has many limitations in itself, such as
reproducibility, between visit variability, a lack of
standardisation as to what constitutes a normal or abnormal
field, the need for three examinations averaged as a baseline to
assess the average mean deviation and decibel loss over time,
and the occurrence of false positives and negatives which
support the performance of repeat tests. Finally, findings from
this study should not be extrapolated to the use of sildenafil for
erectile dysfunction or for other reasons.
62
Conclusions
The main purpose of the pivotal study and its open label
extension was to investigate the overall efficacy and systemic
safety of sildenafil in patients with pulmonary arterial
hypertension during short term and long term chronic daily
exposure. The ocular safety and visual function evaluation was
anadditionalcomponentbasedonnewlyemergingocularsafety
signals with the use of sildenafil on an as needed basis for the
indicationoferectiledysfunction.Thedatashowthatsildenafil,
taken three times daily at doses up to four times the usual
recommended dose for erectile dysfunction, is not associated
with compromised visual function or ocular adverse events.
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RESEARCHWhat is already known on this topic
The phosphodiesterase type 5 inhibitor sildenafil citrate has an established safety profile for intermittent use in the management of
erectile dysfunction
It is approved in the United States and Europe as daily oral therapy for the chronic treatment of pulmonary arterial hypertension, a
progressive debilitating disease
Relevant literature suggests a low incidence of minor, transient ocular effects mediated by partial inhibition of phosphodiesterase type
6 (PDE6), and a recent study in sheep showed intraocular pressure elevated within one hour post-dose
What this study adds
This phase III study allowed objective assessment of visual function parameters for most patients through 18 months of treatment and
collection of subjective reports of ocular adverse events
A dose related increase in transient ocular adverse events mediated by PDE6, such as chromatopsia, cyanopsia, photophobia, visual
brightness, and visual disturbances, was seen
Chronic oral dosing of sildenafil for treating patients with pulmonary arterial hypertension did not have a detrimental effect on any aspect
of visual function or ocular safety evaluated
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RESEARCHTables
Table 1| Participants’ demographics and baseline characteristics. Values are numbers (percentages) unless stated otherwise
Sildenafil
Placebo (n=70) Characteristic 80 mg (n=71) 40 mg (n=67) 20 mg (n=69)
56 (79) 47 (70) 49 (71) 57 (81) Female sex
48 (15) 51 (15) 47 (14) 49 (17) Mean (SD) age (years)
Racial/ethnic background:
58 (82) 58 (87) 59 (86) 61 (87) White
1 (1) 4 (6) 0 1 (1) Black
9 (13) 2 (3) 6 (9) 2 (3) Asian
3 (4) 3 (5) 4 (6) 6 (9) Other
71 (17) 75 (17) 71 (17) 74 (19) Mean (SD) weight (kg)
WHO functional class:
0 0 0 1 (1) I
28 (39) 23 (34) 24 (35) 32 (46) II
42 (59) 44 (66) 40 (58) 34 (49) III
1 (1) 0 5 (7) 3 (4) IV
Cause of pulmonary arterial hypertension:
46 (65) 43 (64) 44 (64) 42 (60) Idiopathic
21 (30) 20 (30) 21 (30) 22 (31) Connective tissue disease
4 (6) 4 (6) 4 (6) 6 (9) Repaired congenital systemic to pulmonary
shunts
0 5 (8) 1 (1) 0 History of glaucoma or ocular hypertension
14.4 (13.7 to 15.1) 14.9 (14.2 to 15.6) 14.8 (14.0 to 15.6) 15.2 (14.0 to 16.4) Mean (95% CI) intraocular pressure, right eye (mm
Hg)
47/66 (71) 43/66 (65) 48/67 (72) 52/68 (77) Normal visual field, right eye*
1.60 (0.19) (n=63) 1.61 (0.16) (n=61) 1.63 (0.17) (n=58) 1.58 (0.20) (n=62) Mean (SD) contrast sensitivity, right eye
Visual acuity (Snellen), right eye:
51 (72) 48 (72) 51 (74) 44 (63) 20/20
11 (16) 13 (19) 12 (17) 15 (21) 20/30
3 (4) 1 (2) 1 (1) 4 (6) 20/40
2 (3) 0 1 (1) 0 20/60
0 0 0 1 (1) 20/120
4 (6) 5 (8) 4 (6) 6 (9) Missing
*Data missing for two participants in placebo and sildenafil 20 mg groups, one in sildenafil 40 mg group, and five in sildenafil 80 mg group.
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RESEARCHTable 2| Baseline incidence of characteristic ocular abnormalities seen in right heart failure by cause and warfarin treatment, right eye.
Values are numbers (percentages)
Warfarin treatment Cause of pulmonary arterial hypertension†
All participants*
(n=260) Abnormality No (n=146) Yes (n=114)
Associated with connective tissue
disease (n=81) Primary (n=164)
23 (16) 21 (18) 12 (15) 29 (18) 44 (17) Dilated episcleral blood vessels
17 (12) 17 (15) 7 (9) 22 (13) 34 (13) Conjunctival injection
20 (14) 12 (11) 8 (10) 23 (14) 32 (12) Abnormal blood vessels
8 (6) 2 (2) 3 (4) 7 (4) 10 (4) Retinal vein engorgement
1 (1) 2 (2) 1 (1) 2 (1) 3 (1) Conjunctival oedema
*Includes all participants with visual assessment data.
†Data missing for 15 participants.
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RESEARCHTable 3| Changes from baseline to week 12 in contrast sensitivity and best corrected visual acuity (spherical equivalent) in right eye during
12 week, double masked study*
Sildenafil
Placebo (n=68) Measure of visual function 80 mg (n=65) 40 mg (n=66) 20 mg (n=67)
Contrast sensitivity†:
5 (8) 8 (12) 3 (5) 2 (3) Improvement
41 (63) 40 (61) 44 (66) 44 (65) No change
9 (14) 5 (8) 5 (8) 9 (13) Deterioration
10 (15) 13 (20) 15 (22) 13 (19) Missing
Visual acuity‡:
2 (3) 1 (2) 5 (8) 7 (10) Improvement
53 (82) 53 (80) 50 (75) 46 (68) No change
5 (8) 3 (5) 2 (3) 7 (10) Deterioration
5 (8) 9 (14) 10 (15) 8 (12) Missing
*Data are numbers (percentages) and include all participants with week 12 visit.
†Improvement=increase of ≥0.15 in log contrast sensitivity; no change=change of <0.15 in log contrast sensitivity; deterioration=decrease of ≥0.15 in log contrast
sensitivity; and missing=not possible to calculate owing to missing data; P=0.039 for comparison in contrast sensitivity improvement between sildenafil 40 mg and
placebo groups.
‡Improvement=increase of ≥1 line read versus baseline (baseline assessment 6/60, 6/36, 6/24, 6/18, 6/12, or 6/9); no change=no change in number of lines read
compared with baseline or change within last three lines of chart (6/6, 6/5, or 6/4); deterioration=decrease of ≥1 line compared with baseline (baseline assessment
6/60, 6/36, 6/24, 6/18, 6/12, 6/9, or 6/6); and missing=not possible to calculate owing to missing data.
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RESEARCHTable 4| Overall frequency of visual field changes in right eye during 12 week, double masked study*
Result at baseline
Result at week 12 Treatment Missing† Abnormal Normal
4 (6) 4 (6) 39 (57) Normal Placebo (n=68)
1 (2) 2 (3) 7 (10) Abnormal
5 (7) 0 6 (9) Missing†
2 (3) 5 (8) 43 (64) Normal Sildenafil 20 mg (n=67)
0 4 (6) 2 (3) Abnormal
5 (8) 3 (5) 3 (5) Missing†
6 (9) 7 (11) 34 (52) Normal Sildenafil 40 mg (n=66)
1 (2) 3 (5) 1 (2) Abnormal
2 (3) 4 (6) 8 (12) Missing†
2 (3) 3 (5) 38 (58) Normal Sildenafil 80 mg (n=66)
2 (3) 8 (12) 3 (5) Abnormal
3 (5) 1 (2) 6 (9) Missing†
*Data are numbers (percentages) and include all participants with week 12 visit.
†Not possible to calculate owing to missing assessment.
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RESEARCHTable 5| Incidence of all causality eye disorder adverse events reported during 12 week, double masked study, either eye. Values are
numbers (percentages, 95% CI)
Sildenafil
Placebo (n=70) Adverse event (MedDRA preferred term) 80 mg (n=71) 40 mg (n=67) 20 mg (n=69)
0 1 (1.5, 0.04 to 8.04) 2 (2.9, 0.35 to 10.08) 0 Abnormal sensation in eye
0 0 0 1 (1.4, 0.04 to 7.70) Accommodation disorder
0 0 1 (1.4, 0.04 to 7.81) 1 (1.4, 0.04 to 7.70) Blepharitis
0 1 (1.5, 0.04 to 8.04) 0 1 (1.4, 0.04 to 7.70) Cataract bilateral NOS
0 1 (1.5, 0.04 to 8.04) 0 0 Cataract unilateral
3 (4.2, 0.88 to 11.86) 1 (1.5, 0.04 to 8.04) 1 (1.4, 0.04 to 7.81) 1 (1.4, 0.04 to 7.70) Chromatopsia
1 (1.4, 0.04 to 7.60) 0 0 0 Conjunctival haemorrhage
0 1 (1.5, 0.04 to 8.04) 1 (1.4, 0.04 to 7.81) 0 Conjunctival hyperaemia
1 (1.4, 0.04 to 7.60) 1 (1.5, 0.04 to 8.04) 0 1 (1.4, 0.04 to 7.70) Conjunctivitis
3 (4.2, 0.88 to 11.86) 1 (1.5, 0.04 to 8.04) 0 0 Cyanopsia
1 (1.4, 0.04 to 7.60) 1 (1.5, 0.04 to 8.04) 1 (1.4, 0.04 to 7.81) 0 Diplopia
0 0 1 (1.4, 0.04 to 7.81) 0 Dry eye NOS
0 0 0 2 (2.9, 0.35 to 9.94) Episcleral hyperaemia
1 (1.4, 0.04 to 7.60) 1 (1.5, 0.04 to 8.04) 1 (1.4, 0.04 to 7.81) 1 (1.4, 0.04 to 7.70) Eye haemorrhage NOS
0 0 0 1 (1.4, 0.04 to 7.70) Eye inflammation NOS
2 (2.8, 0.34 to 9.81) 0 2 (2.9, 0.35 to 10.08) 0 Eye irritation
0 0 0 1 (1.4, 0.04 to 7.70) Eye oedema
3 (4.2, 0.88 to 11.86) 0 1 (1.4, 0.04 to 7.81) 1 (1.4, 0.04 to 7.70) Eye pain
0 1 (1.5, 0.04 to 8.04) 0 1 (1.4, 0.04 to 7.70) Eye pruritus
0 1 (1.5, 0.04 to 8.04) 0 1 (1.4, 0.04 to 7.70) Eye redness
0 0 1 (1.4, 0.04 to 7.81) 1 (1.4, 0.04 to 7.70) Eyelid oedema
2 (2.8, 0.34 to 9.81) 0 0 1 (1.4, 0.04 to 7.70) Halo vision
0 1 (1.5, 0.04 to 8.04) 0 0 Lacrimation increased
0 1 (1.5, 0.04 to 8.04) 0 1 (1.4, 0.04 to 7.70) Lenticular opacities
0 0 1 (1.4, 0.04 to 7.81) 0 Macular oedema
0 1 (1.5, 0.04 to 8.04) 0 0 Ocular discomfort
0 0 1 (1.4, 0.04 to 7.81) 0 Ocular hyperaemia
1 (1.4, 0.04 to 7.60) 0 0 0 Ocular vascular disorder
4 (5.6, 1.56 to 13.80) 0 0 0 Photophobia
1 (1.4, 0.04 to 7.60) 0 0 0 Photophobia aggravated
0 1 (1.4, 0.04 to 8.04) 0 0 Retinal disorder
1 (1.4, 0.04 to 7.60) 2 (3.0, 0.36 to 10.37) 1 (1.4, 0.04 to 7.81) 0 Retinal haemorrhage
1 (1.4, 0.04 to 7.60) 0 0 0 Retinal pigment epitheliopathy
4 (5.6, 1.56 to 13.80) 2 (3.0, 0.36 to 10.37) 3 (4.3, 0.91 to 12.18) 4 (5.7, 1.58 to 13.99) Vision blurred
1 (1.4, 0.04 to 7.60) 2 (3.0, 0.36 to 10.37) 0 0 Visual acuity reduced
2 (2.8, 0.34 to 9.81) 0 0 0 Visual brightness
5 (7.0, 2.33 to 15.67) 3 (4.5, 0.93 to 12.53) 0 0 Visual disturbance NOS
1 (1.4, 0.04 to 7.60) 0 0 0 Xanthopsia
MedDRA=Medical Dictionary for Regulatory Activities; NOS=not otherwise specified.
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RESEARCHTable 6| Overall frequency of ocular findings based on slit lamp and funduscopy examinations in right eye at baseline and week 12 during
12 week, double masked study*
Result at baseline
Result at week 12 Treatment Missing† Abnormal Normal
Serous retinal detachment
4 (6) – 60 (86) Normal Placebo (n=70)
– – – Abnormal
– 5 (7) Missing†
8 (12) – 57 (83) Normal Sildenafil 20 mg (n=69)
– – – Abnormal
– – 4 (6) Missing†
6 (9) – 56 (84)‡ Normal Sildenafil 40 mg (n=67)
– – – Abnormal
– – 4 (6) Missing†
7 (10) – 61 (86) Normal Sildenafil 80 mg (n=71)
– – – Abnormal
– – 2 (3) Missing†
Choroidal detachment
4 (6) – 60 (86) Normal Placebo (n=70)
– – – Abnormal
– – 5 (7) Missing†
8 (12) – 57 (83) Normal Sildenafil 20 mg (n=69)
– – – Abnormal
– – 4 (6) Missing†
6 (9) – 56 (84)‡ Normal Sildenafil 40 mg (n=67)
– – – Abnormal
– – 4 (6) Missing†
7 (10) – 61 (86) Normal Sildenafil 80 mg (n=71)
– – – Abnormal
– – 2 (3) Missing†
Conjunctival injection
3 (4) 4 (6) 47 (67) Normal Placebo (n=70)
2 (3) 8 (11) – Abnormal
– – 5 (7) Missing†
7 (10) 4 (6) 49 (71) Normal Sildenafil 20 mg (n=69)
1 (1) 2 (3) 2 (3) Abnormal
– 1 (1) 3 (4) Missing†
6 (9) 6 (9) 43 (64) Normal Sildenafil 40 mg (n=67)
– 6 (9) 2 (3) Abnormal
– – 4 (6) Missing†
7 (10) 3 (4) 47 (66) Normal Sildenafil 80 mg (n=71)
– 9 (13) 2 (3) Abnormal
– 1 (1) 1 (1) Missing†
Conjunctival oedema
5 (7) 1 (1) 56 (80) Normal Placebo (n=70)
– 1 (1) 1 (1) Abnormal
– – 5 (7) Missing†
8 (12) 1 (1) 55 (80) Normal Sildenafil 20 mg (n=69)
– 1 (1) – Abnormal
– – 4 (6) Missing†
6 (9) 1 (2) 56 (84) Normal Sildenafil 40 mg (n=67)
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RESEARCHTable 6 (continued)
Result at baseline
Result at week 12 Treatment Missing† Abnormal Normal
– – – Abnormal
– – 4 (6) Missing†
7 (10) 1 (1) 60 (85) Normal Sildenafil 80 mg (n=71)
– – – Abnormal
– – 2 (3) Missing†
Dilated episcleral blood vessels
3 (4) 4 (6) 45 (64) Normal Placebo (n=70)
2 (3) 8 (11) 2 (3) Abnormal
– 1 (1) 4 (6) Missing†
5 (7) 5 (7) 44 (64) Normal Sildenafil 20 mg (n=69)
3 (4) 6 (9) 2 (3) Abnormal
– 1 (1) 3 (4) Missing†
5 (8) 5 (8) 46 (69) Normal Sildenafil 40 mg (n=67)
1 (2) 5 (8) 1 (2) Abnormal
– 1 (2) 3 (4) Missing†
5 (7) 6 (9) 43 (61) Normal Sildenafil 80 mg (n=71)
2 (3) 8 (11) 4 (6) Abnormal
– 2 (3) – Missing†
Abnormal blood vessels
4 (6) 3 (4) 48 (69) Normal Placebo (n=70)
– 6 (9) 3 (4) Abnormal
– 1 (1) 4 (6) Missing†
7 (10) 2 (3) 47 (68) Normal Sildenafil 20 mg (n=69)
1 (1) 5 (7) 2 (3) Abnormal
– 1 (1) 2 (4) Missing†
6 (9) 1 (2) 50 (75) Normal Sildenafil 40 mg (n=67)
– 6 (9) – Abnormal
– – 4 (6) Missing†
5 (7) 3 (4) 51 (72) Normal Sildenafil 80 mg (n=71)
2 (3) 4 (6) 3 (4) Abnormal
– – 2 (3) Missing†
Retinal vein engorgement
4 (6) 4 (6) 55 (79) Normal Placebo (n=70)
– 1 (1) – Abnormal
– 1 (1) 4 (6) Missing†
8 (12) – 53 (77) Normal Sildenafil 20 mg (n=69)
– 4 (6) – Abnormal
– – 4 (6) Missing†
6 (9) 1 (2) 51 (76)‡ Normal Sildenafil 40 mg (n=67)
– 3 (5) 1 (2) Abnormal
– – 4 (6) Missing†
7 (10) 1 (1) 59 (83) Normal Sildenafil 80 mg (n=71)
– 1 (1) – Abnormal
– – 2 (3) Missing†
No of participants with ocular abnormalities
1 (1) 4 (6) 36 (51) Normal Placebo (n=70)
3 (4) 19 (27) 1 (1) Abnormal
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RESEARCHTable 6 (continued)
Result at baseline
Result at week 12 Treatment Missing† Abnormal Normal
1 (1) 2 (3) 3 (4) Missing†
4 (6) 7 (10) 34 (49) Normal Sildenafil 20 mg (n=69)
4 (6) 12 (17) 4 (6) Abnormal
– 2 (3) 2 (3) Missing†
5 (8) 7 (10) 31 (46) Normal Sildenafil 40 mg (n=67)
1 (2) 17 (25) 2 (3) Abnormal
– 1 (2) 3 (5) Missing†
4 (6) 8 (11) 31 (44) Normal Sildenafil 80 mg (n=71)
3 (4) 17 (24) 5 (7) Abnormal
1 (1) 2 (3) Missing†
*Data are numbers (percentages) and include all participants with week 12 visit.
†Not possible to calculate change owing to missing assessment.
‡Assessment not done for 1 participant.
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RESEARCHTable 7| Cross tabulation of double masked study dose groups by dose during open label extension study
Double masked study Open label extension study
Sildenafil 80 mg tid (n=64) Sildenafil 40 mg tid (n=63) Sildenafil 20 mg tid (n=65) Placebo (n=67) Sildenafil dose (mg tid) Visit
63 (100) 65 (100) 67 (100) 40 Week 12
64 (100) 80
1 (2) 2 (3) 20 Week 18
1 (2) 20 (32) 16 (25) 23 (34) 40
63 (98) 42 (67) 49 (75) 39 (58) 80
1 (2) 1 (2) 2 (3) 20 Week 24
2 (3) 1 (2) 1 (2) 40
62 (97) 62 (98) 62 (95) 56 (84) 80
1 (2) 2 (3) 20 Month 9
2 (3) 1 (2) 1 (2) 40
61 (95) 61 (97) 61 (94) 54 (81) 80
1 (2) 2 (3) 20 Month 12
2 (3) 1 (2) 1 (2) 40
58 (92) 56 (89) 60 (92) 49 (73) 80
1 (2) 20 Month 15
2 (3) 1 (2) 1 (2) 40
41 (64) 45 (71) 38 (59) 36 (54) 80
1 (2) 1 (2) 40 Month 18
21 (33) 26 (41) 22 (34) 17 (25) 80
1 (2) 1 (2) 40 Month 21
4 (6) 8 (13) 4 (6) 4 (6) 80
1 (2) 1 (2) 20 Month 33
2 (3) 1 (2) 1 (2) 40
54 (84) 56 (89) 55 (85) 47 (70) 80
tid=three times daily.
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RESEARCHTable 8| Incidence of all causality eye disorder adverse events reported by participants by last visit,* either eye. Values are numbers
(percentages, 95% CI)
Sildenafil (n=259) Adverse event (MedDRA preferred term)
1 (0.4, 0.01 to 2.13) Abnormal sensation in eye
2 (0.8, 0.09 to 2.76) Cataract
1 (0.4, 0.01 to 2.13) Cataract bilateral NOS
1 (0.4, 0.01 to 2.13) Cataract cortical
1 (0.4, 0.01 to 2.13) Cataract nuclear
2 (0.8, 0.09 to 2.76) Cataract unilateral
1 (0.4, 0.01 to 2.13) Choroidal detachment
7 (2.7, 1.09 to 5.49) Chromatopsia
12 (4.6, 2.42 to 7.95) Conjunctival hyperaemia
1 (0.4, 0.01 to 2.13) Conjunctival oedema
2 (0.8, 0.09 to 2.76) Conjunctivitis
1 (0.4, 0.01 to 2.13) Conjunctivitis allergic
4 (1.5, 0.42 to 3.91) Cyanopsia
2 (0.8, 0.09 to 2.76) Diplopia
2 (0.8, 0.09 to 2.76) Dry eye NOS
10 (3.9, 1.87 to 6.99) Episcleral hyperaemia
1 (0.4, 0.01 to 2.13) Episcleritis NOS
2 (0.8, 0.09 to 2.76) Eye disorder NOS
6 (2.3, (0.85 to 4.97) Eye haemorrhage NOS
1 (0.4, 0.01 to 2.13) Eye inflammation NOS
3 (1.2, 0.24 to 3.35) Eye irritation
3 (1.2, 0.24 to 3.35) Eye pain
1 (0.4, 0.01 to 2.13) Eye pruritus
3 (1.2, 0.24 to 3.35) Eye redness
1 (0.4, 0.01 to 2.13) Eye swelling
1 (0.4, 0.01 to 2.13) Eyelid disorder NOS
1 (0.4, 0.01 to 2.13) Eyelid oedema
2 (0.8, 0.09 to 2.76) Eyelid ptosis
1 (0.4, 0.01 to 2.13) Glaucoma NOS
2 (0.8, 0.09 to 2.76) Halo vision
1 (0.4, 0.01 to 2.13) Iris vascular disorder NOS
2 (0.8, 0.09 to 2.76) Keratitis
1 (0.4, 0.01 to 2.13) Keratoconjunctivitis sicca
2 (0.8, 0.09 to 2.76) Lacrimation increased
4 (1.5, 0.42 to 3.91) Lenticular opacities
2 (0.8, 0.09 to 2.76) Macular degeneration
1 (0.4, 0.01 to 2.13) Macular oedema
5 (1.9, 0.63 to 4.45) Ocular discomfort
2 (0.8, 0.09 to 2.76) Ocular vascular disorder
1 (0.4, 0.01 to 2.13) Papilloedema
5 (1.9, 0.63 to 4.45) Photopsia
1 (0.4, 0.01 to 2.13) Presbyopia
2 (0.8, 0.09 to 2.76) Punctate keratitis
4 (1.5, 0.42 to 3.91) Refractive errors NOS
1 (0.4, 0.01 to 2.13) Retinal exudates
10 (3.9, 1.87 to 6.99) Retinal haemorrhage
1 (0.4, 0.01 to 2.13) Retinal microaneurysms
3 (1.2, 0.24 to 3.35) Retinal pigmentation
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RESEARCHTable 8 (continued)
Sildenafil (n=259) Adverse event (MedDRA preferred term)
2 (0.8, 0.09 to 2.76) Retinal tear
21 (8.1, 5.09 to 12.13) Vision blurred
3 (1.2, 0.24 to 3.35) Visual acuity reduced
4 (1.5, 0.42 to 3.91) Visual brightness
15 (5.8, 3.28 to 9.37) Visual disturbance NOS
MedDRA=Medical Dictionary for Regulatory Activities; NOS=not otherwise specified.
*Counts of adverse events include data up to seven days after last dose of study drug.
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RESEARCHFigure
Treatment allocation schedule during open label extension study. During first six weeks, participants who did not tolerate
initial sildenafil three times daily dose were allowed to down-titrate to half dose; participants were also allowed to down-titrate
once during first 12 weeks
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RESEARCH